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To the Editors:
Background
Treatment for HIV is lifelong and sustained adherence to treatment is critical to ensure
virological suppression (1–3), particularly among children and adolescents who have poorer
treatment outcomes than adults with limited information on their adherence (4,5). With low
or erratic adherence to treatment, drug levels drop allowing a window of opportunity for
virus multiplication and selection of drug-resistant viral strains(6). Therefore, continued
careful monitoring of adherence is critical to promptly identify and rectify treatment
challenges.
Methods
We conducted a trial of a lay worker delivered treatment support intervention to improve
adherence among children aged 6 to 15 years newly diagnosed with HIV infection, in
Harare, Zimbabwe. HIV treatment was provided according to national guidelines and
treatment adherence was assessed at 48 weeks post ART initiation using the ACTG
adherence follow up questionnaire, adapted for this age-group, and administered by research
nurses (7). Participants or participants together with their caregivers were asked if they had
missed doses over the past three days, over weekends in the past month (as studies have
shown some people find it difficult to take their ART medications on weekends), and over
the past three months. Separately, for all participants we probed about specific reasons for
missing drug doses over the past month. This question was worded, “People may miss their
medications for various reasons. Here is a list of possible reasons why this can happen. In
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the past month have you missed taking your medications because you…” (Figure 1b). The
list of reasons was derived from studies that have reported reasons for non-adherence in this
age-group (8–10). In addition, participants completed a visual analogue scale (VAS) to self-
assess their adherence over the past month. Blood samples for HIV viral-load testing were
collected using routine phlebotomy and were analysed using the dual-target COBAS®
AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0 (11). All statistical analysis were carried
out using Stata 14.0 (StataCorp). Age was coded into two groups, 6-11 and 12-17.
Results
At 48 weeks post ART initiation, of the 237 children who initiated ART, adherence data on
173 (73.0%) children (median age 11 (IQR 9-13) years, 55% female) was available. Of the
72 participants in the 6-11 years age group 59 (82%) answered the adherence questions
together with a relative. However among the 12-17 years age group 79/101 (78%)
participants responded to questions alone. In 3 cases only a relative responded, without the
participant. Overall 89 (51.4%) participants responded to the questions alone. Only 3 (1.7%)
participants reported missing all their ART doses during the past 3 days, 11 (6.4%)
participants reported missing doses on weekends in the past month while 14 (8.2%) reported
having stopped taking their ART medicines for 2 days or longer in the past three months
(Figure 1a). On the VAS 28 (16.2%) participants reported taking less than 95% of their
medication in the previous month and 14 (8.1%) reported taking less than 90%. However,
more participants (n=47, 27.2%) reported having missed doses when asked if they had
missed doses for any of the given reasons in the past month.
The most common reasons for missing ART doses were directly linked to personal lifestyle:
forgetting to take medication (n=32, 18.7%), being away from home (n=14, 8.1%) and
falling asleep during dose times (n=10, 5.9%). Only 1 participant reported missing doses for
each of the clinical or health system related reasons such as having too many pills to take,
feeling sick/ill or clinic stock outs (Figure 1b). Among participants who had a viral load
measurement at 48 weeks post ART initiation 61/166 (36.7%) were not virally suppressed.
Of the 28 participants who scored <95% on the VAS and had a viral load test result 16
(59%) were unsuppressed, compared to 45/139 (32%) who scored ≥95%. VAS score was
strongly associated with viral suppression (OR=0.33, 95%CI 0.14-0.77, p=0.01). There was
no association between respondent (participant versus participant plus relative) and reported
adherence, type for non-adherence or viral suppression, nor between age and the same
outcomes.
Conclusion
In busy clinic settings, adherence is predominantly assessed by asking patients if they have
taken doses, which is subject to both desirability and recall bias (12,13). Our findings
highlight that the greatest challenges for adherence in this group were directly linked to
participants’ daily routines and forgetfulness. We found that probing for possible reasons
why participants may have missed doses yielded higher accuracy for identifying non-
adherence than asking participants whether they were missing doses. The possible reasons
for this may have been that asking specific reasons for missing doses acted as a memory
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trigger for participants who may have forgotten missing doses or had not considered these
instances as poor adherence. We also found that while non-adherence is underreported, when
participants do report non-adherence it is a strong indicator of a high HIV viral load.
Although viral load is the gold standard to assess adherence, it is not routinely available in
many resource-limited settings (14). Assessing short term adherence and probing to explore
the possible reasons why participants miss doses should be used by health care workers in
order to obtain more accurate measures for ART adherence.
In our study the responses were given by either caregivers on behalf of the child, jointly by
caregivers and children or children alone (for older children). The scales routinely used to
measure reported non-adherence have been mainly designed for use among adults, and there
are no corresponding scales for children (15). Considerations must be made to validate and
adapt self-reported adherence measures for children and to link what health care workers
consider as non-adherence to what children and adolescents and their caregivers construe as
non-adherence.
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Figure 1.
a: Participant responses to Adherence Questionnaire and Viral Load Results (N=173)
b: Reasons reported for missing doses
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